Endologix (ELGX) Given Media Impact Rating of 0.14

News articles about Endologix (NASDAQ:ELGX) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 47.9012984310504 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of brokerages have recently commented on ELGX. Canaccord Genuity reissued a “hold” rating on shares of Endologix in a report on Friday, August 4th. BidaskClub cut Endologix from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 target price on Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. Stifel Nicolaus set a $6.00 target price on Endologix and gave the company a “hold” rating in a research note on Wednesday, August 2nd. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 target price on shares of Endologix in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating and eleven have given a hold rating to the company’s stock. Endologix has an average rating of “Hold” and a consensus target price of $6.13.

Shares of Endologix (NASDAQ ELGX) traded up $0.07 during midday trading on Friday, reaching $5.06. The company’s stock had a trading volume of 695,200 shares, compared to its average volume of 619,033. Endologix has a 12-month low of $4.08 and a 12-month high of $10.36. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.12.

TRADEMARK VIOLATION NOTICE: This news story was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/12/endologix-elgx-given-media-impact-rating-of-0-14.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply